Therefore, our study has identified PHF20 as a key factor of GBM growth and development via regulation of β-Catenin through a WISP1 and BGN dependent mechanism, thus serving as a crucial biomarker for GBM diagnosis and a therapeutic target for treatment. The gene discussed is PHF20; the disease is glioblastoma.